A detailed history of Wells Fargo & Company transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 102,475 shares of IBRX stock, worth $366,860. This represents 0.0% of its overall portfolio holdings.

Number of Shares
102,475
Previous 53,685 90.88%
Holding current value
$366,860
Previous $288,000 124.65%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$4.82 - $9.15 $235,167 - $446,428
48,790 Added 90.88%
102,475 $647,000
Q1 2024

May 10, 2024

BUY
$3.23 - $6.17 $7,535 - $14,394
2,333 Added 4.54%
53,685 $288,000
Q4 2023

Feb 09, 2024

BUY
$1.25 - $5.21 $14,747 - $61,467
11,798 Added 29.83%
51,352 $257,000
Q3 2023

Nov 13, 2023

SELL
$1.29 - $3.1 $31,474 - $75,636
-24,399 Reduced 38.15%
39,554 $66,000
Q2 2023

Aug 15, 2023

BUY
$1.53 - $6.41 $47,200 - $197,748
30,850 Added 93.19%
63,953 $177,000
Q1 2023

May 12, 2023

BUY
$1.35 - $4.78 $25,312 - $89,625
18,750 Added 130.63%
33,103 $60,000
Q4 2022

Feb 13, 2023

SELL
$4.35 - $6.77 $18,909 - $29,429
-4,347 Reduced 23.25%
14,353 $72,000
Q3 2022

Nov 14, 2022

BUY
$3.65 - $6.43 $8,989 - $15,837
2,463 Added 15.17%
18,700 $93,000
Q2 2022

Aug 12, 2022

SELL
$2.68 - $6.14 $313,675 - $718,644
-117,043 Reduced 87.82%
16,237 $61,000
Q1 2022

May 16, 2022

BUY
$5.05 - $7.53 $48,702 - $72,619
9,644 Added 7.8%
133,280 $748,000
Q4 2021

Feb 14, 2022

SELL
$5.67 - $10.18 $8,907 - $15,992
-1,571 Reduced 1.25%
123,636 $752,000
Q3 2021

Nov 15, 2021

SELL
$9.17 - $14.24 $331,587 - $514,918
-36,160 Reduced 22.41%
125,207 $1.22 Million
Q2 2021

Aug 16, 2021

BUY
$13.41 - $22.4 $1.47 Million - $2.46 Million
109,900 Added 213.53%
161,367 $2.3 Million
Q1 2021

May 13, 2021

BUY
$12.83 - $42.25 $660,321 - $2.17 Million
51,467 New
51,467 $1.22 Million

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.43B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.